Stay updated on Pembrolizumab vs Placebo in Stage II Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Placebo in Stage II Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab vs Placebo in Stage II Melanoma Clinical Trial page
- CheckyesterdayChange DetectedA site-wide NIH notice says agencies are transitioning from the term “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check8 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check15 days agoChange DetectedThe footer revision number changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check36 days agoChange DetectedRevision: v3.7.0 was added; sponsor-related and document references were removed from the Study Documents section, reducing the amount of linked materials and sponsor identifiers on the page.SummaryDifference19%

- Check57 days agoChange DetectedAn NIH grant/contract note for 2018 was added to the funding disclosures. The revision tag was updated from v3.6.5 to v3.6.6, replacing the previous revision.SummaryDifference0.0%

- Check64 days agoChange DetectedMelanoma, the related topics heading, and the MedlinePlus Genetics link were removed from the page. This consolidates the page's related-topic references to focus more on the study details.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab vs Placebo in Stage II Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Placebo in Stage II Melanoma Clinical Trial page.